Genetic Technologies Announces Divestment of Australian Based Heritage Business
September 22, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Sep 22, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce that it has signed a binding contract of sale for its...
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing
September 15, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Sep 15, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to announce plans for the restructure and realignment of group...
Genetic Technologies Announces Further Patent Success in USA
August 26, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Aug 26, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the United States District Court for the Middle District of...
Alchemia Appoints Jenni Pilcher as Chief Financial Officer
August 25, 2014 05:30 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Aug 25, 2014) - Alchemia Limited (ASX: ACL), a drug discovery and development company, announced today the appointment of Ms. Jenni Pilcher as its Chief Financial...
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
July 30, 2014 05:30 ET
|
Proteostasis Therapeutics
CAMBRIDGE, MA--(Marketwired - Jul 30, 2014) - Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with...
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014
July 07, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jul 7, 2014) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the number of...
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
June 30, 2014 05:15 ET
|
Proteostasis Therapeutics
CAMBRIDGE, MA--(Marketwired - Jun 30, 2014) - Proteostasis Therapeutics, Inc., a developer of novel therapeutics regulating protein homeostasis to improve outcomes for patients with orphan and...
Alchemia Announces First Patient Enrolled in Investigator-Led Phase II Trial of HA-Irinotecan and Erbitux ("CHIME" Trial)
June 20, 2014 05:30 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Jun 20, 2014) - Alchemia Limited (ASX: ACL), a drug discovery and development company, today announced that the first patient has been enrolled into the new...
Alchemia Updates Timeline for Completion of Pivotal Phase III Trial of HA-Irinotecan in Metastatic Colorectal Cancer
June 05, 2014 19:51 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Jun 5, 2014) - Alchemia Limited (ASX: ACL), a drug discovery and development company, announced today that they expect to report the top-line results from the...
Genetic Technologies Announces Appointment of Chief Financial Officer
May 28, 2014 22:51 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - May 28, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce the appointment of Mr Eutillio Buccilli to the role of Chief...